Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Non Operating Income (2016 - 2026)

Akebia Therapeutics has reported Non Operating Income over the past 10 years, most recently at -$117000.0 for Q4 2025.

  • Quarterly Non Operating Income fell 312.73% to -$117000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58000.0 through Dec 2025, down 38.3% year-over-year, with the annual reading at $58000.0 for FY2025, 38.3% down from the prior year.
  • Non Operating Income was -$117000.0 for Q4 2025 at Akebia Therapeutics, down from -$10000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $1.3 million in Q2 2021 and troughed at -$117000.0 in Q4 2025.
  • The 5-year median for Non Operating Income is $187000.0 (2021), against an average of $329900.0.
  • Year-over-year, Non Operating Income skyrocketed 604.35% in 2022 and then plummeted 312.73% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $560000.0 in 2021, then dropped by 22.5% to $434000.0 in 2022, then surged by 51.61% to $658000.0 in 2023, then tumbled by 91.64% to $55000.0 in 2024, then plummeted by 312.73% to -$117000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Non Operating Income are -$117000.0 (Q4 2025), -$10000.0 (Q3 2025), and -$28000.0 (Q2 2025).